Fig. 5From: Clinical research of the value of high-risk CTV setting on intensity-modulated radiotherapy for stage IIB-IVA cervical cancerA OS rate of stage IIIC2 in the EG and CG. B PFS rate of stage IIIC2 in the EG and CG. C In-field PFS rate of stage IIIC2 in the EG and CG. D Out-field PFS of stage IIIC2 in the EG and CG. EG, experimental group; CG, control groupBack to article page